Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - duloxetine hydrochloride 33.7mg equivalent to duloxetine base 30 mg;   - modified release capsule - 30 mg - active: duloxetine hydrochloride 33.7mg equivalent to duloxetine base 30 mg   excipient: ammonia solution colour mixture white ddb8257w gelatin hypromellose hypromellose acetate succinate indigo carmine ink purified talc sodium laurilsulfate sucrose sugar spheres titanium dioxide triethyl citrate

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - duloxetine hydrochloride, quantity: 67.32 mg - capsule, enteric - excipient ingredients: hypromellose; dichloromethane; purified water; isopropyl alcohol; hyprolose; purified talc; titanium dioxide; crospovidone; triethyl citrate; hypromellose phthalate; iron oxide yellow; gelatin; sodium lauryl sulfate; indigo carmine aluminium lake; maize starch; sucrose - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of diabetic peripheral neuropathic pain (dpnp).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - duloxetine hydrochloride, quantity: 33.66 mg - capsule, enteric - excipient ingredients: triethyl citrate; hypromellose; purified water; isopropyl alcohol; hyprolose; purified talc; dichloromethane; hypromellose phthalate; crospovidone; titanium dioxide; quinoline yellow; gelatin; sodium lauryl sulfate; patent blue v; maize starch; sucrose - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of diabetic peripheral neuropathic pain (dpnp).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 67.36 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; purified talc; pregelatinised maize starch; lactose monohydrate; hypromellose; triethyl citrate; polysorbate 80; isopropyl alcohol; hypromellose phthalate; magnesium stearate; dichloromethane; methanol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; iron oxide yellow; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid; indigo carmine aluminium lake; ethanol; strong ammonia solution; iron oxide black - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 33.68 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; lactose monohydrate; croscarmellose sodium; dichloromethane; polysorbate 80; hypromellose; pregelatinised maize starch; magnesium stearate; methanol; purified talc; isopropyl alcohol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; ethanol; strong ammonia solution; iron oxide black; indigo carmine; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

alembic pharmaceuticals limited - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of major depressive disorder (mdd). the efficacy of duloxetine delayed-release capsules were established in four short term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. duloxetine delayed-release capsules are indicated for the treatment of generalized anxiety disorder (gad). the efficacy of duloxetine delayed-release capsules were established in three short-term trials and o

Канада - Енглески - Health Canada

mylan pharmaceuticals ulc - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 30mg - duloxetine (duloxetine hydrochloride) 30mg - selective serotonin and norepinephrine-reuptake inhibitors

Канада - Енглески - Health Canada

jamp pharma corporation - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 30mg - duloxetine (duloxetine hydrochloride) 30mg - selective serotonin and norepinephrine-reuptake inhibitors